Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Craig TJ, Reshef A, Li HH, Jacobs JS, Bernstein JA, Farkas H, Yang WH, Stroes ESG, Ohsawa I, Tachdjian R, Manning ME, Lumry WR, Saguer IM, Aygören-Pürsün E, Ritchie B, Sussman GL, Anderson J, Kawahata K, Suzuki Y, Staubach P, Treudler R, Feuersenger H, Glassman F, Jacobs I, Magerl M. Craig TJ, et al. Among authors: glassman f. Lancet. 2023 Apr 1;401(10382):1079-1090. doi: 10.1016/S0140-6736(23)00350-1. Epub 2023 Feb 28. Lancet. 2023. PMID: 36868261 Clinical Trial.
Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 study.
Fukuda T, Yamagami K, Kawahata K, Suzuki Y, Sasaki Y, Miyagi T, Jacobs I, Lawo JP, Glassman F, Akama H, Hide M, Ohsawa I. Fukuda T, et al. Among authors: glassman f. Allergol Int. 2023 Jul;72(3):451-457. doi: 10.1016/j.alit.2023.02.002. Epub 2023 Feb 28. Allergol Int. 2023. PMID: 36858856 Free article. Clinical Trial.
Systemic IgG exposure and safety in patients with primary immunodeficiency: a randomized crossover study comparing a novel investigational wearable infusor versus the Crono pump.
Wasserman RL, Cunningham-Rundles C, Anderson J, Lugar P, Palumbo M, Patel NC, Hofmann J, Glassman F, Rogers E, Praus M, Rojavin MA. Wasserman RL, et al. Among authors: glassman f. Immunotherapy. 2022 Nov;14(16):1315-1328. doi: 10.2217/imt-2022-0097. Epub 2022 Sep 21. Immunotherapy. 2022. PMID: 36128795 Free article. Clinical Trial.
Chondromalacia patellae.
SIDEMAN S, GLASSMAN F, WOLIN I. SIDEMAN S, et al. Among authors: glassman f. Surg Clin North Am. 1949 Feb;29(1):261-7. doi: 10.1016/s0039-6109(16)32648-2. Surg Clin North Am. 1949. PMID: 18124112 No abstract available.
12 results